Today: 5 June 2026
Singtel share price edges up as Nxera opens Tuas AI-ready data centre, cyber risk lingers

Singtel share price edges up as Nxera opens Tuas AI-ready data centre, cyber risk lingers

Singapore, Feb 10, 2026, 15:14 SGT — Regular session

  • Singtel edged up roughly 0.2% in mid-afternoon action, trading close to its recent record highs.
  • Nxera has launched its biggest multi-tenant data centre yet in Tuas, touting AI-ready capacity.
  • Investors are sizing up the sector’s growth ambitions as new concerns emerge over telco cyber defences.

Singtel shares edged up Tuesday, with investors eyeing its “digital infrastructure” angle after the company’s data centre unit launched a new AI-focused Tuas facility.

The announcement followed a separate headache: Singapore officials disclosed specifics of a cyberattack on the nation’s top telecom operators. For investors, it’s another sign—the very networks they favor also draw unwanted attention from hackers.

Here’s why it matters right now: Singtel isn’t acting like a standard telco lately. The stock’s behaving more like a network utility fused with a data centre play, leaving investors to figure out what kind of growth premium to grant — and how much to shave off for regulatory and security risks.

Singtel edged up 0.2% to S$4.79, just above its prior finish at S$4.78, with shares moving in a band from S$4.72 to S$4.81 during the session. The Straits Times Index slipped 0.07%.

Nxera kicked off operations at DC Tuas on Monday, rolling out a 58-megawatt center Singtel touts as built for higher rack densities—the kind of power-hungry server arrays needed for AI model training and deployment. “Higher-density” AI workloads are fast turning “increasingly critical,” according to Bill Chang, Nxera’s chief executive and head of Singtel’s Digital InfraCo unit, especially in a market “where data centre capacity is constrained.” The Business Times

Singapore authorities disclosed that all four major telecom players—Singtel, StarHub, M1, and Simba—were hit by a UNC3886 cyberattack. No indication so far that customer data has been compromised. Mandiant, owned by Google, calls UNC3886 a “suspected China-nexus espionage actor.” Officials detailed that one breach saw hackers slip past a perimeter firewall using a “zero-day exploit,” exploiting a software bug unknown and unpatched at the time. A limited amount of technical data was taken. CNA

Investors aren’t wondering if the stock can talk up AI — that pitch is already out there. The question now: do increased security budgets, stricter oversight, or recurring outages begin to bite in the numbers? Telcos count as critical infrastructure, so trouble doesn’t usually stay in just one bucket.

Singtel shares have jumped in recent days after the company, teaming up with KKR, struck a deal to acquire all of ST Telemedia Global Data Centres (STT GDC), valuing the operator at S$13.8 billion. The transaction, pending regulatory signoff, is slated to close in the second half of 2026.

Still, the narrative could shift. Building data centres in Singapore comes with heavy upfront costs, and constraints on electricity and land can drag out expansion timelines; a sudden regulatory pivot or a broader security breach might flip the risk equation fast—particularly for operators dealing with sensitive data flows.

Singtel’s earnings drop Feb. 18. Traders want details—especially from Singapore’s cyber agencies—about whether the intrusion attempts are continuing, and what the remediation bill might look like.

Stock Market Today

  • MoonLake Immunotherapeutics CFO Sells Small Stake Under Prearranged Plan, No Investor Alarm
    June 4, 2026, 10:41 PM EDT. MoonLake Immunotherapeutics (MLTX) CFO Matthias Bodenstedt sold 13,653 shares, about 1.1% of his holdings, in a Rule 10b5-1 trading plan on May 11, 2026. This plan allows insiders to sell shares on a preset schedule to avoid allegations of insider trading. Bodenstedt retains over 1.17 million shares, valued at $22 million post-transaction. The sale is smaller than his April 2026 disposition and involves no derivative holdings. MoonLake, a clinical-stage biotech developing sonelokimab for inflammatory diseases, faces a 63% share price drop over the past year but remains a high-risk, potentially high-reward stock with positive drug trial results. Analysts largely rate it a Buy despite the firm's pre-revenue status and significant net losses.

Latest articles

Dow Hits Record, But Wall Street Watches After-Hours Session

Dow Hits Record, But Wall Street Watches After-Hours Session

5 June 2026
Dow soared to a record close, but after-hours jitters hit as Broadcom missed revenue expectations and cut its AI-chip forecast, dragging chip stocks and exposing markets to Friday’s key jobs report, which could sway rates, yields, and tech valuations. Lululemon shares plunged 11% after slashing its profit outlook.
AT&T Stock Drops, Investors Eye SpaceX’s Move

AT&T Stock Drops, Investors Eye SpaceX’s Move

5 June 2026
AT&T shares plunged 3.3% to $22.77 after a Supreme Court loss and an Oppenheimer downgrade citing rising satellite broadband competition, as SpaceX’s $75 billion IPO nears; investors fear AT&T’s fiber-heavy strategy faces new risks, with Oppenheimer warning broadband and mobile growth could be at risk from low Earth orbit rivals.
Marvell rises as chip peers drop, Wall Street eyes index move

Marvell rises as chip peers drop, Wall Street eyes index move

5 June 2026
Marvell jumped 4.9% to $316.43, defying a chip selloff, as traders bet on S&P 500 inclusion and Nvidia-linked AI demand; the stock later slipped to $305.18 after hours, with volume more than double average, as investors await Friday’s S&P announcement and weigh risks of high expectations and index flows.
Guidewire Beats Earnings but Shares Drop on Revenue Number

Guidewire Beats Earnings but Shares Drop on Revenue Number

5 June 2026
Guidewire Software plunged 13.77% after hours to $130.36 as investors fixated on annual recurring revenue guidance that missed Wall Street’s target by a narrow margin, overshadowing strong earnings and revenue beats; the stock’s sharp drop highlights concerns over contract growth pacing despite raised full-year outlooks and robust financials.
CAR Group share price holds post-results gains as brokers trim targets — what to watch next
Previous Story

CAR Group share price holds post-results gains as brokers trim targets — what to watch next

Seatrium stock inches up as Petrobras arbitration reopens P-54 payment fight
Next Story

Seatrium stock inches up as Petrobras arbitration reopens P-54 payment fight

Go toTop